Activated Jak2-Stat5 signaling can be readily targeted by the current Jak2-inhibitors that have been developed for myeloproliferative disorders (MPDs) and hematological malignancies, which will be reviewed here. This evidence concerns the gene STAT5B and hematologic disorder.